Capecitabine in combination with Docetaxel in first line in HER2-Negative metastatic breast cancer an observational study /
Due to the limited experience with capecitabine plus docetaxel (XT) combination in the first-line treatment of metastatic breast cancer in Hungary, the main objective of the study was to analyze the effectiveness and tolerability of XT therapy. A prospective, open-label, non-randomized, single-arm,...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
Springer Netherlands
2017
|
| Sorozat: | PATHOLOGY AND ONCOLOGY RESEARCH
23 No. 3 |
| doi: | 10.1007/s12253-016-0129-7 |
| mtmt: | 3151638 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/12504 |
| LEADER | 02456nab a2200349 i 4500 | ||
|---|---|---|---|
| 001 | publ12504 | ||
| 005 | 20200303160003.0 | ||
| 008 | 180108s2017 hu o 0|| zxx d | ||
| 022 | |a 1219-4956 | ||
| 024 | 7 | |a 10.1007/s12253-016-0129-7 |2 doi | |
| 024 | 7 | |a 3151638 |2 mtmt | |
| 040 | |a SZTE Publicatio Repozitórium |b hun | ||
| 041 | |a zxx | ||
| 100 | 1 | |a Kószó Renáta Lilla | |
| 245 | 1 | 0 | |a Capecitabine in combination with Docetaxel in first line in HER2-Negative metastatic breast cancer |h [elektronikus dokumentum] : |b an observational study / |c Kószó Renáta Lilla |
| 260 | |a Springer Netherlands |c 2017 | ||
| 300 | |a 505-511 | ||
| 490 | 0 | |a PATHOLOGY AND ONCOLOGY RESEARCH |v 23 No. 3 | |
| 520 | 3 | |a Due to the limited experience with capecitabine plus docetaxel (XT) combination in the first-line treatment of metastatic breast cancer in Hungary, the main objective of the study was to analyze the effectiveness and tolerability of XT therapy. A prospective, open-label, non-randomized, single-arm, multicenter, observational study was designed. All female patients were eligible whose metastatic breast cancer could be treated with the XT protocol according to the summary of product characteristics of the drugs. The median progression free survival was 9.9 ± 3.0 months. Time to treatment failure was 4.6 ± 5.1 months on average. The overall response rate was 28.9 %, the clinical benefit rate was 73.3 %. The treatment was discontinued in 35.6 % of patients due to disease progression and in 20.0 % due to adverse events (AE). 33 patients with a total of 73 AEs have been reported, and 13 of them had serious adverse events (SAE). The efficacy and the safety profile of XT chemotherapy proven in the study are consistent with the results demonstrated in randomized trials. First-line XT chemotherapy effectively improves the PFS in metastatic breast cancer. Keywords CapecitabineDocetaxelHER2-negative metastatic breast cancerToxicity | |
| 700 | 0 | 1 | |a Sántha Dóra |e aut |
| 700 | 0 | 1 | |a Büdi László |e aut |
| 700 | 0 | 1 | |a Erfán József |e aut |
| 700 | 0 | 1 | |a Győrfy Károly |e aut |
| 700 | 0 | 1 | |a Horváth Zsolt |e aut |
| 700 | 0 | 1 | |a Kocsis Judit |e aut |
| 700 | 0 | 1 | |a Landherr László |e aut |
| 700 | 0 | 1 | |a Hitre Erika |e aut |
| 700 | 0 | 1 | |a Máhr Károly |e aut |
| 700 | 0 | 1 | |a Pajkos Gábor |e aut |
| 700 | 0 | 1 | |a Pápai Zsuzsanna |e aut |
| 700 | 0 | 1 | |a Kahán Zsuzsanna |e aut |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/12504/1/s12253_016_0129_7_u.pdf |z Dokumentum-elérés |